TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate with bone metastases~* Treatment decision for Radium-223 according to local label needs to be made independent from and before patient enrollment in the study by the investigator~* No contra-indications according to the local marketing authorization~Exclusion Criteria:~* Previously treated with Radium-223 for any reason~* Currently treated in clinical trials including other Radium-223 studies or planned participation in an investigational program with interventions outside of routine clinical practice during the study period

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRPC patients (Type: None): Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine Alone or in Combination for Malaria in Children in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one or more of the following:~  1. fever at the time of evaluation (axillary temperature greater than or equal to 37.5 degrees Celsius by digital thermometer)~ 2. report of fever within the last two days~ 3. clinically profound anemia (conjunctival or palmar pallor)~ 4. headache~ 5. body aches~ 6. abdominal pain~ 7. decreased intake of food or fluids~ 8. weakness~* Weight greater than or equal to 5kg.~* Positive malaria smear for P. falciparum mono-infection with parasite density 2,000-200,000/mm\^3.~* Planning to remain in the study area for 1 year.~* Willingness to return for four-weekly routine visits, as well as unscheduled sick visits.~* Parental/guardian consent for each participant.~Exclusion Criteria:~* Signs of severe malaria: One or more of the following:~  1. hemoglobin less than or equal to 5 g/dL~ 2. prostration~ 3. respiratory distress~ 4. bleeding~ 5. recent seizures, coma or obtundation (Blantyre coma score \< 5)~ 6. inability to drink~ 7. persistent vomiting~* Known allergy or history of adverse reaction to chloroquine (CQ), artesunate, azithromycin, erythromycin or atovaquone-proguanil (AP)~* Chronic medication with any antibiotic or anti malarial medication~* Previous enrollment in this study~* Alanine aminotransferase (ALT) more than 5x the upper limit of normal or creatinine greater than 3x the upper limit of normal~* Evidence of chronic disease or physical stigmata of severe malnutrition (i.e., loss of muscle mass or subcutaneous tissue, edema, or skin or hair findings consistent with severe malnutrition)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- CQ Monotherapy (Type: EXPERIMENTAL): N=160: treat with Chloroquine (CQ) alone.
- CQ plus atovaquone proguanil (Type: EXPERIMENTAL): N=160: treat with CQ plus atovaquone proguanil.
- CQ plus artesunate (Type: EXPERIMENTAL): N=160: treat with CQ plus artesunate.
- CQ plus azithromycin (Type: EXPERIMENTAL): N=160: treat with CQ plus azithromycin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Bone Loss After Acute SCI by Zoledronic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In-patient at Rehabilitation Institute of Chicago (RIC) or an outpatient who was recently discharged from RIC~* Males and females~* Age \>/=18 years~* Medically stable in the opinion of subject's physiatrist~* SCI at within 120 days inclusive at time of screening~* SCI with inability to ambulate independently~* ASIA Impairment Scale (AIS) A, B, or C, at time of study entry~* Capable of positioning to have DXA performed~* Able to tolerate acetaminophen~* No known endocrinopathies (diabetes type 1 or 2 can be included)~* Normal TSH levels~* Normal 25-OH vitamin D levels (\>/= 20 ng/ml) at baseline (subjects may be repleted)~* Normal calcium levels~* Normal renal function (creatinine \<2.0 mg/dl)~* Well hydrated with adequate intake of liquids~* Able to return for all follow-up visits~* Capable of reading and understanding informed consent document~* Males and females of childbearing potential must be willing and able to use double barrier method of contraception for 2 months after having received study drug~Exclusion Criteria:~* Have Paget's disease of the bone~* Malignancy as a cause of acute SCI~* Have unexplained high levels of alkaline phosphatase in blood~* Any active gastrointestinal condition that results in malabsorption~* Poor dental hygiene or requirement for invasive dental procedure within two months prior to enrollment~* History of bone metastasis and skeletal malignancies~* History of alcoholism or drug abuse within the 2 years prior to study screening~* Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study~* Elevated liver function tests \>2x normal~* Currently being prescribed anti-convulsants at a dose or frequency that is determined to interfere with bone metabolism as determined by the investigator~* Currently being prescribed glucocorticoids, other than inhaled glucocorticoids~* Current or recent use any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds within 60 days of screening.~* Pregnant, planning to become pregnant, or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zol (Type: EXPERIMENTAL): Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
- Placebo (Type: EXPERIMENTAL): Intravenous infusion of placebo at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~Patients with type 2 diabetes (drug naive or pre-treated) with insufficient glycaemic control (HbA1c higher or equal than 7.5 to less than 11.0 %), with very poor glycaemic control (HbA1c higher or equal than 11.0 %) who are not eligible for randomisation to be included in the open-label arm~Exclusion criteria:~Myocardial infarction, stroke or transient ischemic attack (TIA), unstable or acute congestive heart failure, impaired hepatic function, treatment with rosiglitazone or pioglitazone, with a GLP1 analogue, with insulin, with anti-obesity drugs, with systemic steroids, renal failure or impairment, gastric bypass

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 + metformin (Type: EXPERIMENTAL): BI 1356 low dose + metformin 500 mg, twice daily
- matching placebo (Type: PLACEBO_COMPARATOR): matching placebo
- BI 1356+ Metformin (Type: EXPERIMENTAL): BI 1356 low dose + metformin 1000 mg, twice daily
- Metformin (Type: ACTIVE_COMPARATOR): Metformin 500 mg, twice daily
- metformin (Type: ACTIVE_COMPARATOR): Metformin 1000 mg, twice daily
- BI 1356 (Type: EXPERIMENTAL): BI 1356 high dose, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged from 6 months to 65 years old~* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum (or mixed with non-falciparum species)~* Asexual P. falciparum parasitaemia: 5,000 to 200,000/uL, de-termined on a thin or thick blood film (In Cambodia patients with a parasitaemia of 16 to 200,000/uL are eligible. In DRC patients with a parasitaemia of 10,000 to 250,000/ul are eligi-ble)~* Fever defined as \>/= 37.5°C tympanic temperature or a history of fever within the last 24 hours~* Written informed consent (by parent/guardian in case of children)~* Willingness and ability of the patients or parents/guardians to comply with the study protocol for the duration of the study~Exclusion Criteria:~* Signs of severe/complicated malaria~* Haematocrit \< 25% or Hb \< 5 g/dL at screening (DRC: Hct\<15% and Hb \<5 g/dL due to high prevalence of anemia).~* Acute illness other than malaria requiring treatment~* For females: pregnancy, breast feeding~* Patients who have received artemisinin or a derivative or an artemisinin containing combination therapy (ACT) within the previous 7 days~* Treatment with mefloquine in the 2 months prior to presentation will be an exclusion criteria in the DHA-P+MQ sites~* History of allergy or known contraindication to artemisinins, or to the ACT or TACT to be used at the site e.g. neuropsychiatric disorders will be a contraindication for the use of mefloquine.~* Previous splenectomy~* QTc-interval \> 450 milliseconds at moment of presentation~* Documented or claimed history of cardiac conduction problems~* Earlier participation within the TRACII trial or another trial in the previous 3 months.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ACT-arms (Type: ACTIVE_COMPARATOR): 1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days
- TACT-arms (Type: ACTIVE_COMPARATOR): 2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability of the participant or his legally authorized representative (e.g., parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local participant privacy regulations~* Male participants of any age diagnosed with severe hemophilia A (as confirmed from the medical record)~* Currently diagnosed with high titer inhibitors (historical peak greater than or equal to (\>=) 5 Bethesda units per milliliter (BU/mL), according to medical records)~* Previously treated with any plasma-derived or recombinant conventional or Extended Half-Life FVIII~Exclusion Criteria:~* Other coagulation disorder(s) in addition to hemophilia A~* Previous immune tolerance induction (ITI)~* History of hypersensitivity or anaphylaxis associated with any factor VIII (FVIII) administration~* Planned major surgery scheduled during the study unless deferred until after study completion (minor surgery such as tooth extraction or insertion/replacement of central venous access device is allowed)~* Abnormal renal function (serum creatinine \>1.5 milligram per deciliter (mg/dL) or 2 × upper limit of normal (ULN) for participant age based on local laboratory range) as assessed by local laboratory~* Serum alanine aminotransferase or aspartate aminotransferase \> 5 × upper limit of normal (ULN) as assessed by local laboratory

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Recombinant coagulation factor VIII Fc (rFVIIIFc) (Type: EXPERIMENTAL): Participants were to receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who met the criteria for immune tolerance induction (ITI) success entered the tapering period and received rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up was for 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Male or female patients, 18 to 75 years of age,~* Confirmed clinico-pathological diagnosis of eosinophilic esophagitis (EoE) according to established diagnostic criteria~* Active symptomatic and histological EoE,~* A documented trial with proton pump inhibitors (PPIs) in order to rule out PPI-responsive esophageal eosinophilia,~* Negative pregnancy test in females of childbearing potential at baseline visit.~Exclusion Criteria:~* Clinical and endoscopic signs of gastroesophageal reflux disease (GERD),~* History of abnormal results in case of an optionally performed pH-monitoring of the distal esophagus,~* Patients with PPI-responsive esophageal eosinophilia~* Achalasia, scleroderma esophagus, or systemic sclerosis,~* Other clinically evident causes than EoE for esophageal eosinophilia,~* Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection \[candida esophagitis\]),~* Any relevant systemic disease (e.g., AIDS, active tuberculosis),~* If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection,~* Liver cirrhosis or portal hypertension,~* History of cancer in the last five years,~* History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit,~* Upper gastrointestinal bleeding within 8 weeks prior to screening visit,~* Existing or intended pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): Budesonide 1mg orodispersible tablet twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo orodispersible tablet twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Female, aged 18 to 45 years, inclusive~* Have moderate to severe pelvic pain due to endometriosis~* Have been surgically (laparoscopy) diagnosed with endometriosis within the last 5 years and have recurrent or persistent endometriosis symptoms~* Have regular menstrual cycle (23-33 day)~* Agree to use two forms of non-hormonal contraception during the study~Exclusion Criteria:~* Received a Gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, danazol, or have received any of these agents within 6 months of the start of screening.~* Received subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular (i.m.) medroxyprogesterone acetate (DMPA-IM), or have received either of these agents within 3 months of the start of screening.~* Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month~* Have had surgery for endometriosis within the last month~* Are using systemic steroids on a chronic or regular basis within 3 months~* Have uterine fibroids or other pelvic lesions ≥ 3 cm in diameter~* Have had a hysterectomy or oophorectomy~* Have pelvic pain that is not caused by endometriosis~* Have unstable medical condition or chronic disease~* Have been pregnant within the last 6 months and is currently breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
- Elagolix 150 mg (Type: EXPERIMENTAL): Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
- Elagolix 250 mg (Type: EXPERIMENTAL): Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
- Leuprorelin (Type: OTHER): Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Luteal Phase Administration of Paroxetine for the Treatment of PMDD

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PMDD according to DSM-IV criteria~Exclusion Criteria:~* Women were excluded if they were taking oral contraception, breast-feeding, pregnant, or planning to become pregnant during the study period.~* Women were also excluded if they met DSM-IV criteria for any Axis I disorder, were deemed a suicidal risk, had a history of SSRI use for premenstrual symptoms, were taking ongoing medication that could affect PMDD symptoms, had a clinically significant abnormality on screening blood tests, or had a baseline Montgomery-Asberg Depression Rating Scale score of equal to or greater than 10 during the follicular phase of the menstrual cycle.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Paroxetine 10mg;paroxetine 20mg; Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus.~* Managed by diet therapy.~* Must have adequate blood, liver and kidney function.~Exclusion criteria:~* Serious cardiovascular disease or serious hepatic disease.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate Effect on Humphrey Visual Fields

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* abnormal visual fields~* must be able to swallow pills~Exclusion Criteria:~* psychiatric disorder~* dementia~* ocular disorder which is known to cause abnormal visual fields~* prescription of psychoactive medications~* visual acuity lower than 20/100~* cardiac arrhythmia~* hypersensitivity to methylphenidate~* prescription of warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- methylphenidate provided (Type: EXPERIMENTAL): the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
- control (Type: ACTIVE_COMPARATOR): control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete